Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows. The three-year-long trial, funded by the drugs' maker, Eli Lilly, also found "sustained weight loss through the treatment period, with adults on the 15-milligram [mg] dose experiencing a 22.9% average decrease in body weight compared to 2.
1% for placebo," the company said in a issued Tuesday. "These data reinforce the potential clinical benefits of long-term therapy for people living with obesity and prediabetes," Dr. Jeff Emmick, senior vice president of product development at Lilly, said in the release.
Tirzepatide is a competitor GLP-1 drug to semaglutide, which is made by Novo Nordisk and branded as Ozempic for and Wegovy for weight loss. Sales of both tirzepatide and semaglutide have boomed in recent years as people flock to the drugs to help lose excess weight. Tirzapatide and semaglutide work by boosting insulin release, helping to increase feelings of fullness and suppressing appetite.
Both injected drugs were originally designed as treatments for diabetes, however. In the new trial, 1,032 people who were deemed to be prediabetic and either obese or overweight received a "dummy" placebo injection weekly or an injection of either 5 mg, 10 mg or 15 mg of tirzepatide for 176 weeks (three years). Participants were deemed to be prediabetic if they had conditions such as , , h.